Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2years of treatment in children with secondary osteoporosis

Bone

Volumn 49, Issue 5, 2011, Pages 939-943

  Simm, Peter J ^a   Johannesen, Jesper ^a   Briody, Julie ^a   McQuade, Mary ^a   Hsu, Brian ^a   Bridge, Corinne ^a   Little, David G ^a,b   Cowell, Christopher T ^a,b   Munns, Craig F ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bisphosphonates; Bone fragility; Fracture; Osteopenia; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; MULTIVITAMIN; OSTEOCALCIN; PHOSPHATE; VITAMIN D; ZOLEDRONIC ACID;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE AGE; BONE DENSITY; BONE MINERAL; BONE PAIN; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CORTICAL BONE; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; HYPOCALCEMIA; LONG BONE; LONG BONE FRACTURE; LUMBAR SPINE; MALE; METACARPAL BONE; METACARPAL CORTICAL THICKNESS; MORPHOMETRICS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; SECONDARY OSTEOPOROSIS; SHORT COURSE THERAPY; THICKNESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRA; VERTEBRA FRACTURE; VERTEBRAL HEIGHT RATIO;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS;

EID: 80054832983     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.031     Document Type: Article

References (32)

1. Munns C.F., Cowell C.T. Prevention and treatment of osteoporosis in chronically ill children. J Musculoskelet Neuronal Interact 2005, 5(3):262-272.
2. Ward L., Tricco A.C., Phuong P., Cranney A., Barrowman N., Gaboury I., et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev (Online) 2007, (4):CD005324.
3. Clark E.M., Tobias J.H., Ness A.R. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics 2006, 117(2):e291-e297.
4. Henderson R.C., Lark R.K., Kecskemethy H.H., Miller F., Harcke H.T., Bachrach S.J. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002, 141(5):644-651.
5. Golden N.H., Iglesias E.A., Jacobson M.S., Carey D., Meyer W., Schebendach J., et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005, 90(6):3179-3185.
6. Rudge S., Hailwood S., Horne A., Lucas J., Wu F., Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005, 44(6):813-818.
7. El-Husseini A.A., El-Agroudy A.E., El-Sayed M.F., Sobh M.A., Ghoneim M.A. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004, 8(4):357-361.
8. Brown J.J., Zacharin M.R. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 2009, 22(1):55-63.
9. Vuorimies I., Toiviainen-Salo S., Hero M., Makitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 2011, 75(5):346-353.
10. Panigrahi I., Das R.R., Sharda S., Marwaha R.K., Khandelwal N. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 2010, 28(4):451-455.
11. Sbrocchi A.M., Forget S., Laforte D., Azouz E.M., Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010, 52(5):754-761.
12. August K.J., Dalton A., Katzenstein H.M., George B., Olson T.A., Wasilewski-Masker K., et al. The use of zoledronic acid in pediatric cancer patients. Pediatr Blood Cancer 2011, 56(4):610-614.
13. Hough J.P., Boyd R.N., Keating J.L. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics 2010, 125(3):e670-e678.
14. Bachrach L.K., Ward L.M. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009, 94(2):400-409.
15. Baim S., Leonard M.B., Bianchi M.L., Hans D.B., Kalkwarf H.J., Langman C.B., et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008, 11(1):6-21.
16. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002, (246):1-190.
17. Carter D.R., Bouxsein M.L., Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992, 7(2):137-145.
18. Lu P.W., Briody J.N., Ogle G.D., Morley K., Humphries I.R., Allen J., et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994, 9(9):1451-1458.
19. Ogle G.D., Allen J.R., Humphries I.R., Lu P.W., Briody J.N., Morley K., et al. Body-composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26y. Am J Clin Nutr 1995, 61(4):746-753.
20. Hogler W., Briody J., Woodhead H.J., Chan A., Cowell C.T. Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 2003, 143(1):81-88.
21. Greulich W., Pyle S. Radiographic atlas of skeletal development of the hand and wrist 1959, Standford University Press, Stanford, 1.
22. Land C., Rauch F., Munns C.F., Sahebjam S., Glorieux F.H. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006, 39(4):901-906.
23. Genant H.K., Wu C.Y., van Kuijk C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8(9):1137-1148.
24. Munns C.F., Rajab M.H., Hong J., Briody J., Hogler W., McQuade M., et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007, 41(3):366-370.
25. Gleeson H., Wiltshire E., Briody J., Hall J., Chaitow J., Sillence D., et al. Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 2008, 35(4):707-712.
26. Whyte M.P., Wenkert D., Clements K.L., McAlister W.H., Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 31 2003, 349(5):457-463.
27. Marini J.C. Bone: use of bisphosphonates in children-proceed with caution. Nat Rev 2009, 5(5):241-243.
28. Johannesen J., Briody J., McQuade M., Little D.G., Cowell C.T., Munns C.F. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone 2009, May 13.
29. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 24 2004, 363(9418):1377-1385.
30. Rauch F., Travers R., Munns C., Glorieux F.H. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004, 19(7):1191-1193.
31. Munns C.F., Rauch F., Ward L., Glorieux F.H. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004, 19(10):1742-1745.
32. Brown J.J., Ramalingam L., Zacharin M.R. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?. Clin Endocrinol 2008, 68(6):863-867.